{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:13:48Z","timestamp":1784636028947,"version":"3.55.0"},"reference-count":37,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, immune-related adverse events (irAEs) increase morbidity and mortality and thereby limit therapeutic utility. The real-world incidence of the entire spectrum of pulmonary irAEs has not been systematically described. The objective of this study is to assess the risk of developing pulmonary irAEs (pneumonitis, pleural events [i.e., effusion and pleurisy], exacerbations of airway disease [i.e., bronchitis and bronchiectasis], and sarcoidosis) with exposure to five commonly used ICIs: nivolumab, pembrolizumab, durvalumab, avelumab, and atezolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of the Food and Drug Administration Adverse Events Reporting System (FAERS) pharmacovigilance database. We collected data from 2012 to 2021 to assess the risk of pulmonary irAEs and performed a disproportionality analysis using Open-Vigil, a software package used for analysis of pharmacovigilance data, to calculate reporting odds ratios (RORs). We used 95% CIs to evaluate the precision of RORs. An ROR greater than 1 and the upper limit of the 95% CI indicated statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17,273,403 events were reported in FAERS between 2012 and 2021. Of these, 88,099 (0.5%) were attributed to the PD-1 (programmed cell death protein 1) inhibitors and 21,905 (0.1%) to PD-L1 (programmed death ligand 1) inhibitors of interest. The most common indication for using the ICIs of interest was lung cancer: a total of 2832 (46.70%) for the PD-1 inhibitors and 1311 (70.9%) for the PD-L1 inhibitors. In the anti\u2013PD-1 group, 2342 (38.6%) patients were hospitalized, and 1962 (32.4%) patients died from the lung adverse event. In the PD-L1 group, 744 (40.3%) patients were hospitalized, and 520 (28.1%) patients died from the event. Nivolumab resulted in the highest statistically significant risk (ROR, 10.5; 95% CI, 10.1\u201310.9) for pneumonitis. Avelumab had a lesser risk for pneumonitis (ROR, 0.2; 95% CI, 0.2\u20130.3). The risk for pleural events was highest with nivolumab (ROR, 3.6; 95% CI, 3.4\u20133.9), followed by pembrolizumab (ROR, 1.8; 95% CI; 1.6\u20132.0) (p &amp;lt; 0.001), with the lowest risks from durvalumab, atezolizumab, and avelumab. For ICI-related sarcoidosis, the risk was most significant with pembrolizumab (ROR, 3.6; 95% CI, 2.8\u20134.7), followed by nivolumab (ROR, 2.5; 95% CI, 1.9\u20133.5) (p &amp;lt; 0.001). The RORs for all five ICIs were less than 1 for exacerbations of airway diseases as compared with other drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using a pharmacovigilance database, we found an increased risk of multiple pulmonary irAEs after ICI therapy, particularly with PD-1 inhibitors. Further work is needed to investigate the incidence of pulmonary irAEs other than pneumonitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-22-38","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T13:23:21Z","timestamp":1692365001000},"page":"177-184","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance"],"prefix":"10.36401","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5750-2787","authenticated-orcid":true,"given":"Ugochi","family":"Ebinama","sequence":"first","affiliation":[{"name":"1 Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"2 Department of Pulmonary Medicine, Division of Internal Medicine, Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Anand","sequence":"additional","affiliation":[{"name":"3 Callahan Cancer Center, Great Plains Health, North Platte, NE, USA"},{"name":"4 Mission Cancer and Blood, Des Moines, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyer","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"5 Department of Lymphoma\/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"2023120211584960500_i2590-017X-6-4-177-b01","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"2023120211584960500_i2590-017X-6-4-177-b02","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023120211584960500_i2590-017X-6-4-177-b03","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4081\/oncol.2020.490","article-title":"Are anti-PD1 and anti-PD-L1 alike: the non-small-cell lung cancer paradigm","volume":"14","author":"Banna","year":"2020","journal-title":"Oncol Rev"},{"key":"2023120211584960500_i2590-017X-6-4-177-b04","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"CMAJ"},{"key":"2023120211584960500_i2590-017X-6-4-177-b05","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"2023120211584960500_i2590-017X-6-4-177-b06","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3389\/fphar.2021.743582","article-title":"Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer","volume":"12","author":"Rapoport","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b07","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"2023120211584960500_i2590-017X-6-4-177-b08","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors: an overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"key":"2023120211584960500_i2590-017X-6-4-177-b09","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"key":"2023120211584960500_i2590-017X-6-4-177-b10","year":"2022","journal-title":"Questions and Answers on FDA's Adverse Event Reporting System (FAERS). United States Food and Drug Administration website. Accessed April 8,"},{"key":"2023120211584960500_i2590-017X-6-4-177-b11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b12","first-page":"614","volume":"114","author":"Bukamur","year":"2021","journal-title":"Immune checkpoint inhibitor-related pulmonary toxicity: a comprehensive review, part II. South Med J"},{"key":"2023120211584960500_i2590-017X-6-4-177-b13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"2023120211584960500_i2590-017X-6-4-177-b15","first-page":"668765","volume":"12","author":"Khouri","year":"2021","journal-title":"Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances."},{"key":"2023120211584960500_i2590-017X-6-4-177-b16","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.18295\/squmj.2021.21.02.001","article-title":"Al, Varughese SS. Pharmacovigilance: basic concepts and an overview of the system in Oman","volume":"21","author":"Jose","year":"2021","journal-title":"Sultan Qaboos Univ Med J"},{"key":"2023120211584960500_i2590-017X-6-4-177-b17","year":"2022","journal-title":"A smoky immune response in lung cancer patients. Accessed December 3,"},{"key":"2023120211584960500_i2590-017X-6-4-177-b18","doi-asserted-by":"crossref","first-page":"2000038","DOI":"10.1183\/13993003.00038-2020","article-title":"Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis","volume":"55","author":"Moey","year":"2020","journal-title":"Eur Respir J"},{"key":"2023120211584960500_i2590-017X-6-4-177-b19","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b20","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/cncr.34229","article-title":"Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: a retrospective cohort study","volume":"128","author":"Sheshadri","year":"2022","journal-title":"Cancer"},{"key":"2023120211584960500_i2590-017X-6-4-177-b21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"2023120211584960500_i2590-017X-6-4-177-b22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"2023120211584960500_i2590-017X-6-4-177-b24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023120211584960500_i2590-017X-6-4-177-b25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling","volume":"9","author":"de Sousa Linhares","year":"2019","journal-title":"Sci Rep"},{"key":"2023120211584960500_i2590-017X-6-4-177-b26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2023120211584960500_i2590-017X-6-4-177-b27","first-page":"1","article-title":"Sarcoidosis reactivation with immune checkpoint inhibitors","volume":"4","author":"Creusot","year":"2020","journal-title":"Cancer Rep Rev"},{"key":"2023120211584960500_i2590-017X-6-4-177-b28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2023120211584960500_i2590-017X-6-4-177-b29","doi-asserted-by":"crossref","first-page":"590494","DOI":"10.3389\/fimmu.2020.590494","article-title":"Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b30","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.3747\/co.26.4859","article-title":"Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer","volume":"26","author":"Blanchard","year":"2019","journal-title":"Curr Oncol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b31","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2023120211584960500_i2590-017X-6-4-177-b32","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"2023120211584960500_i2590-017X-6-4-177-b33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b35","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"2023120211584960500_i2590-017X-6-4-177-b36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pds.4344","article-title":"An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance","volume":"27","author":"Pinheiro","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023120211584960500_i2590-017X-6-4-177-b37","volume-title":"Practical aspects of signal detection in pharmacovigilance","year":"2010"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/177\/3296248\/i2590-017x-6-4-177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/177\/3296248\/i2590-017x-6-4-177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:19Z","timestamp":1765475299000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/4\/article-p177.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,2]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-22-38","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}